No Data
No Data
No Data
No Data
No Data
Yahong Pharmaceutical (688176.SH)'s revenue in the first quarter increased 126% month-on-month
On April 29, Yahong Pharmaceutical (stock code: 688176.SH) released its report for the first quarter of 2024. The company achieved revenue of 243.195 million yuan in the first quarter, an increase of 126.08% over the previous quarter. This was mainly due to the company's sales of commercial products, pezopanib tablets (trade name: Dipite) and neratinib maleate tablets (trade name: OUBI) during the reporting period. Depat and Oubi went on sale in October and December 2023 respectively, and product sales increased in the first quarter of this year.
Gelonghui FinanceApr 29 06:30 ET
Yahong Pharmaceutical (688176.SH) announced 2023 annual results, all core products are under development, and net loss increased to 400 million yuan
Yahong Pharmaceutical (688176.SH) disclosed its 2023 annual report. The company achieved operating income of 13 during the reporting period...
Zhitong FinanceApr 17 10:20 ET
Yahong Pharmaceutical: Significant revenue growth in 2023 Core product APL-1702? New drug marketing applications are expected to be accepted in Q2
Gelonghui, April 17 | Yahong Pharmaceutical released its annual report. In 2023, the company achieved operating income of 13.7533 million yuan, an increase of 137.272 million yuan over the same period last year. The revenue growth was mainly due to sales revenue and license fee revenue generated by prazopanib tablets and neratinib maleate tablets in Q4 of 2023. In addition, the company's core products have made many advances. For example, APL-1702 is actively preparing to submit a new drug marketing application, and Q2 is expected to be accepted; APL-1706's new drug marketing application has been accepted; and APL-1202 and PD-1's phase II clinical trial analysis has been positive
Gelonghui FinanceApr 17 09:47 ET
Yahong Pharmaceutical (688176.SH): APL-1706 has reached the main research endpoint of phase III clinical trials. The application for marketing has been accepted
Yahong Pharmaceutical (688176.SH) announced that the company APL-1706 is a multi-center for bladder cancer diagnosis...
Zhitong FinanceApr 8 03:49 ET
Yahong Pharmaceutical (688176.SH): Release of APL-1702 international multi-center phase III clinical trial data for the treatment of high-grade squamous intraepithelial lesion of the cervix
Gelonghui, March 18 | Yahong Pharmaceutical (688176.SH) announced that recently, Jiangsu Yahong Pharmaceutical Technology Co., Ltd. product APL1702 for treating high-grade cervical squamous intraepithelial lesion (HSIL) prospective, randomized, double-blind, placebo-controlled international multi-center phase III clinical trial results were selected for the 2024 European Genital Infection and Oncology Research Organization Conference (EUROGIN) and 2024 American Gynecological Oncology Society Annual Meeting (SGO), and
Gelonghui FinanceMar 18 03:42 ET
While Institutions Invested in Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Benefited From Last Week's 10% Gain, Retail Investors Stood to Gain the Most
Key Insights The considerable ownership by retail investors in Jiangsu Yahong Meditech indicates that they collectively have a greater say in management and business strategy 50% of the business is
Simply Wall StMar 14 21:13 ET
No Data
No Data